ClinicalTrials.gg

Program

pegrizeprument

Also written as “VEL-101” and “FR104”.

Its studies are mostly in Arthritis, Rheumatoid, led by 2 companies.

Furthest: phase 2, since Nov 24, 20253 company-led studies, 1 open or runningNext primary completion: Oct 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Veloxis Pharmaceuticals21 open or runningphase 2since Nov 24, 2025Jan 25, 2022Oct 2028phase 2 · NCT07290777
OSE Immunotherapeutics10 open or runningphase 1since May 20, 2016May 20, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2016First study: phase 1 study in Arthritis, RheumatoidNew to OSE ImmunotherapeuticsOSE Immunotherapeutics · NCT02800811 · 64 enrolled · Belgium
  2. Jan 25, 2022Veloxis Pharmaceuticals's first study: phase 1 study in Healthy VolunteersNew to Veloxis PharmaceuticalsVeloxis Pharmaceuticals · NCT05238493 · 60 enrolled · United States
  3. Nov 24, 2025Phase 2 study in Transplantation, KidneyPhase 2 reachedVeloxis Pharmaceuticals · NCT07290777 · 120 planned · United States

Ahead

  1. Oct 2028Primary completion: phase 2 study in Transplantation, KidneyVeloxis Pharmaceuticals · NCT07290777

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07290777Transplantation, Kidney · United States2RecruitingVeloxis PharmaceuticalsOct 2028120
NCT05238493Healthy Volunteers · United States1CompletedVeloxis PharmaceuticalsJan 3, 202360
NCT02800811Arthritis, Rheumatoid · Belgium1CompletedOSE ImmunotherapeuticsJun 201664

How it is read

Names in the registry

  • “VEL-101”, 2 entries
  • “FR104”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.